Navigation Links
Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Date:11/7/2007

Company-Sponsored "Technology Topics" Workshop Scheduled for 1 to 2 pm

Wednesday, Hyatt Regency Century Plaza, Constellation Room A.

WELLESLEY, Mass., Nov. 7 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that the company will launch its Ziplex Automated Gene-Expression System for research use only at the Association for Molecular Pathology (AMP) Annual Meeting and Exhibit, which opens today at the Hyatt Regency Century Plaza Hotel in Los Angeles. The first integrated system designed for automated gene-expression analysis, the Ziplex System comprises an automated workstation, TipChip consumable arrays, and reagents.

Xceed designed the Ziplex System to make routine molecular diagnostics both feasible and affordable. "The routine clinical laboratory will require a system that is reliable and easy to operate," said Xceed's President and CEO, David Deems. "As a fully automated and integrated platform, the Ziplex System is unmatched for both its ease-of-use and reliability of results, delivering superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. The Ziplex System allows researchers to perform testing at approximately one-third the cost and in one-third the time of conventional platforms. After the sample preparation has been completed, the hands-on time to process eight samples is approximately 20 minutes. We believe our System will help make the promise of personalized medicine a reality."

While today is the official launch of the Ziplex System, biomedical researchers across the country are already familiar with the system's performance, according to Deems. The company has been offering Expression Services for the last year, and has presented data at a number of important conferences. Deems continued, "Xceed is developing a pipeline of diagnostic assays for use on the Ziplex System. There is a great deal of interest in focused content - and there are few competitive alternatives. We expect to have a variety of condition- or pathway-specific Signature Chips that will be available both as catalog products and through Xceed's Expression Services. The Metabolic Signature Chip, designed to investigate differential expression associated with diseases of the metabolic system (e.g. muscle disorders, obesity, and other metabolic diseases), is available today. In addition, Xceed now offers the Breast and Colon Cancer Signature Chips. We have a number of other Signature Chips in development for inflammation and for a range of cancers, including prostate, lung, and melanoma. We are actively pursuing licensing arrangements with strategic partners to add other signatures to our pipeline."

The list price for the Ziplex Automated Workstation, which automates the hybridization, imaging, quantitation, and quality control, is $85,000 USD. The TipChip consumable that contains assay-specific content can cost as little as $120 USD per TipChip. (The price will vary based on content.) As part of the AMP launch, Xceed is offering special promotional pricing for early adopters.

Technical Topics Workshop

Xceed is also sponsoring a Technical Topics Workshop at the conference: Translational Research of Gene-Expression Assays to the Ziplex Automated Workstation by David Englert, PhD. Time: 1 to 2 pm, Wed, Nov 7, 2007, Hyatt Regency Century Plaza Hotel Constellation Room A.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex(R) System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, and pre- configured arrays. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit http://www.XceedMolecular.com.


'/>"/>
SOURCE Xceed Molecular
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AdvaMed 2007 Exceeds Attendance Expectations With More Than 1,100 Participants from 35 States and 25 Countries
2. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
3. A new molecular zip code, and a new drug target for Huntingtons disease
4. New knock-out gene model provides molecular clues to breast cancer
5. Molecular probe paints cancer cells in living animals, Stanford researchers find
6. Story ideas from molecular & cellular proteomics
7. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
10. Molecular profiling can accurately predict survival in colon cancer patients
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in North America, today announced it would be offering some it’s exclusive product ... itself on crafting quality and unique baby clothing/feeding products, will team up with ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
(Date:2/27/2017)... , February 27, 2017 Leading Countries, ... market is expected to grow at a CAGR of 8.9% ... expected to grow at a CAGR of 9.1% from 2016 to ... in 2027. ... this report will benefit you Read on to discover how ...
Breaking Medicine Technology: